Jeuveau has been evaluated in clinical studies for safety and approved by the FDA as safe for use in adults
Semaglutide acts on the hypothalamus, the GI tract, and the pancreas simultaneously, producing appetite suppression, gastric emptying delay, and improved insulin secretion as three reinforcing mechanisms
and c) irregular dietary patterns), reduced bioavailability (impairment of the intrinsic factor-mediated absorption pathway, often due to the widespread and prolonged use of proton pump inhibitors), and malabsorption syndromes
Studies that used 1 mg/day in oral and intravenous trials did not show meaningfully better outcomes than lower doses, and higher doses were associated with more reports of headache, diarrhea, and gastrointestinal effects